Myeloproliferative neoplasms, thrombosis and paroxysmal nocturnal hemoglobinuria: Is this triad more frequent than we thought?

Gaidano,M. Geuna,A. Cignetti,F. Carnuccio,P. Bernabei,Nathalie Santoro,G. Saglio,P. Sivera

DOI: https://doi.org/10.15761/HMO.1000132

Abstract:Background: Chronic myeloproliferative neoplasms (MPN) are clonal disorders characterized by an increased risk of thrombosis and of leukemic evolution. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease whose characteristic traits are intravascular hemolysis and thrombophilia. The PNH clone is classically associated with bone marrow failure syndromes and, accordingly, it is thought to expand because the remaining hematopoiesis is suppressed. Conversely, here we report the detection of a PNH population in 2 MPN patients presenting with thrombosis. Case presentation: The first case is a 72-year-old woman presenting with a portal vein thrombosis associated with leukothrombocytosis and anemia; additional investigations diagnosed a JAK2-mutated essential thrombocythemia in myelofibrotic evolution and a significant PNH population. The second case is a 75-year-old man with JAK2-mutated polycythemia vera and a long history of thrombosis, who was found to carry a small PNH clone. Both our patients have experienced severe thrombotic events, while neither of them has ever reported signs of overt hemolysis. Conclusions: These cases defy the most accepted etiopathogenetic theory for PNH, challenge the classical indications for PNH screening and raise several practical questions, such as the clinical significance of small PNH clones and the management of patients with two pro-thrombotic factors with different etiologies. Correspondence to: Alessandro Cignetti, University Division of Hematology and Cell Therapy, AO Ordine Mauriziano, Largo Turati 62, 10128, Turin, Italy, Tel: +39 011 5085322; Fax: +39 011 5085374; E-mail: acignetti@mauriziano.it